دانلود رایگان مقاله لاتین آنتی بادی ضد ویروس کوکساکی از سایت الزویر
عنوان فارسی مقاله:
مدل نوزادان موش برای ارزیابی آنتی بادی ها و واکسن ها ضد ویروس کوکساکی A6
عنوان انگلیسی مقاله:
A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6
سال انتشار : 2016
برای دانلود رایگان مقاله آنتی بادی ضد ویروس کوکساکی اینجا کلیک نمایید.
مقدمه انگلیسی مقاله:
1. Introduction
Hand, foot, and mouth disease (HFMD) is a highly contagious disease that affects infants and children around the world, particularly in the Asia-Pacific region (Lei et al., 2015). Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) have been the predominant causes of HFMD in the last ten years (Lei et al., 2015; Mao et al., 2014; Xing et al., 2014). However, increasing epidemiological data indicates that the number of HFMD epidemics associated with coxsackievirus A6 (CA6) has markedly increased worldwide in recent years (Bian et al., 2015; Feder et al., 2014; Mirand et al., 2012; Montes et al., 2013). Additionally, CA6 has even replaced EV71 and CA16 as the predominant pathogen in some HFMD outbreaks in Europe (Cabrerizo et al., 2014; Kobayashi et al., 2013), Asia (Gopalkrishna et al., 2012; Han et al., 2014; Miyamoto et al., 2014; Wu et al., 2010) and North America (Centers for Disease Control and Prevention, 2012; Fonseca et al., 2014; Klein and Chong, 2015). CA6 belongs to the human enterovirus species A within the Picornaviridae family. CA6-associated HFMD is characterized by widespread vesiculobullous eruption (Stewart et al., 2013), onychomadesis (Osterback et al., 2009; Wei et al., 2011), herpangina (Mirand et al., 2012), and higher rate of infection in adults (Downing et al., 2014), which is different from traditional HFMD caused by EV71 and CA16. Because of the outbreaks of CA6 and the severity of its clinical manifestations, CA6 has recently attracted the attention of researchers around the world. However, studies of CA6 have just begun, and the current body of knowledge on the infection, pathogenic mechanism, and immunogenicity of CA6 is still very limited. The development of an animal model is indispensable in studying the pathogenic mechanism and evaluating the efficacy of vaccines or antiviral reagents. Animal models of EV71 and CA16 have been constructed based on various types of animals, such as neonatal mice, adult immune-deficient mice, transgenic mice and non-human primates (Liu et al., 2014; Wang and Yu, 2014). These animal models have greatly facilitated the process of vaccine development and the understanding of the pathogenesis of HFMD. Specifically, small animal models have been widely used in assessing the efficacy of experimental vaccines at early stages. The increasing number of CA6 epidemics has increased the need for animal models of CA6. However, no neonatal mouse model has been established to evaluate the efficacy of vaccines or therapeutic antibodies against CA6. In a previous study, we reported that an isolated CA6 strain CA6/ 141 could grow in RD cells with high titers and showed high virulence in one-day-old suckling mice (Yang et al., 2015). In this study, a neonatal mouse model was further established based on this CA6 strain, and the pathogenic characteristics of CA6 in mice were analyzed. This mouse model was also applied to evaluate the efficacy of a therapeutic antibody and an experimental vaccine against CA6.
برای دانلود رایگان مقاله آنتی بادی ضد ویروس کوکساکی اینجا کلیک نمایید.
کلمات کلیدی:
[PDF]Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against ... www.mdpi.com/1999-4915/7/11/2916/pdf by EA Caine - 2015 - Cited by 14 - Related articles Nov 17, 2015 - Vaccine against Enterovirus 71 and Coxsackieviruses. A16 and ... Coxsackievirus A6 (CVA6; Picornaviridae; Enterovirus), are involved [2]. .... antibodies to their homologous virus with no detectable levels of cross neutralizing ... Emerging Microbes & Infections - EV-A71 vaccine licensure: a first ... www.nature.com › Journal home › Archive › July 20 2016 Jul 20, 2016 - Among these viruses, EV-A71 and coxsackievirus (CV) CV-A16 from group .... CV-A6 and CV-A10 may also cause HFMD outbreaks, while other viruses in .... that these vaccines may induce animals to generate neutralizing antibodies ... The clinical results showed that the protection rate against HFMD was ... Virus-like particle-based vaccine against coxsackievirus A6 protects ... search.proquest.com/openview/03771ecfe680692a567f4f5a7a4b60f0/1?pq-origsite... by C Shen - 2016 - Related articles Virus-like particle-based vaccine against coxsackievirus A6 protects mice against ... Mice immunized with these VLPs produced CA6-specific serum antibodies. EV71 vaccines: a first step towards multivalent hand, foot and mouth ... www.tandfonline.com/doi/full/10.1586/14760584.2015.993385?src=recsys Dec 24, 2014 - Keywords: coxsackieviruses A16, A6, A10, cross-neutralizing antibody, Enterovirus 71, hand foot and mouth diseases, human enteroviruses A, ... Achievements, challenges and prospects for the development of ... engine.scichina.com/doi/10.1007/s11434-015-0847-3 by L Ke - 2015 - Related articles A few neutralizing monoclonal antibodies against EV71 or CVA16 have been ... of broadly protective vaccines and neutralizing antibodies against HFMD, and ... genomic analysis of coxsackievirus A6 strains of different clinical disease entities. Immunological and biochemical characterizations of coxsackievirus ... https://www.unboundmedicine.com/.../Immunological_and_biochemical_characteriza... Immunological and biochemical characterizations of coxsackievirus A6 and A10 ... CV-A16 multivalent vaccine candidates elicited cross-neutralizing antibody ...
